TYRATECH • ANNUAL REPORT 2014 • PAGE 18
D i re c t o rs ' Remu n e rat i o n Rep o r t ( c o n t ' d )
for, but not entitled to, a sum equal to six times his then current
monthly base salary. If Dr. Jactel's employment is terminated by
a change in control in the Company, Dr. Jactel will be entitled to
a lump sum payment equal to 12 times his then current monthly
base salary plus other benefits. Dr. Jactel will not be eligible for
any kind of severance payment if he resigns from the Company.
NON-EXECUTIVE DIRECTORS' LETTERS OF APPOINTMENT
Mr. Reade and Mr. Riley entered into agreements with the
Company on 25 May 2007, which govern the terms and
conditions of their appointment as Non-Executive Directors of
the Company. Following his appointment on 20 June 2013, as
Non-Executive Chairman, Mr. Reade is entitled to fees totalling
£70,000 per year. Mr. Riley remains entitled to fees of £35,000
per year. Mr. Hills entered into an agreement with the Company
on 9 July 2010 which governs his term and conditions of his
appointment as a Non-Executive Director of the Company. Mr.
Hills is entitled to fees totalling $55,000 per year. Mr. Wintemute,
who was appointed as a Non-Executive Director 20 June 2013,
received no fees during 2013 or 2014.
In addition to fees, the Company reimburses the Independent
Non-Executive Directors for all reasonable out-of-pocket
expenses incurred.
PERFORMANCE GRAPH
The following graph shows the Company's performance,
measured by total shareholder return, compared with the
performance of the FTSE AIM All Share Healthcare Index and the
FTSE AIM All Share Index.
The Directors consider the FTSE AIM All Share Healthcare Index and FTSE AIM All Share Index to be appropriate choices.
